Hostname: page-component-745bb68f8f-f46jp Total loading time: 0 Render date: 2025-01-08T08:46:22.823Z Has data issue: false hasContentIssue false
  • English
  • Français

Carbapenems Versus Piperacillin-Tazobactam for Bloodstream Infections of Nonurinary Source Caused by Extended-Spectrum Beta-Lactamase–Producing Enterobacteriaceae

Published online by Cambridge University Press:  20 May 2015

Hadas Ofer-Friedman ,
Coral Shefler ,
Sarit Sharma ,
Amit Tirosh ,
Ruthy Tal-Jasper ,
Deepthi Kandipalli ,
Shruti Sharma ,
Pradeep Bathina ,
Tamir Kaplansky  and
Moran Maskit
...Show all authors
Hadas Ofer-Friedman
Affiliation:
Unit of Infectious Diseases, Assaf Harofeh Medical Center, Zerifin, Israel
Coral Shefler
Affiliation:
Sackler School of Medicine, Tel-Aviv University, Tel-Aviv, Israel
Sarit Sharma
Affiliation:
Division of Infectious Diseases, Detroit Medical Center, Wayne State University, Detroit, Michigan, USA
Amit Tirosh
Affiliation:
Department of Medicine A, Assaf Harofeh Medical Center, Zerifin, Israel
Ruthy Tal-Jasper
Affiliation:
Sackler School of Medicine, Tel-Aviv University, Tel-Aviv, Israel
Deepthi Kandipalli
Affiliation:
Division of Infectious Diseases, Detroit Medical Center, Wayne State University, Detroit, Michigan, USA
Shruti Sharma
Affiliation:
Division of Infectious Diseases, Detroit Medical Center, Wayne State University, Detroit, Michigan, USA
Pradeep Bathina
Affiliation:
Division of Infectious Diseases, Detroit Medical Center, Wayne State University, Detroit, Michigan, USA
Tamir Kaplansky
Affiliation:
Unit of Infectious Diseases, Assaf Harofeh Medical Center, Zerifin, Israel
Moran Maskit
Affiliation:
Unit of Infectious Diseases, Assaf Harofeh Medical Center, Zerifin, Israel
Tal Azouri
Affiliation:
Unit of Infectious Diseases, Assaf Harofeh Medical Center, Zerifin, Israel
Tsilia Lazarovitch
Affiliation:
Clinical Microbiology Laboratory, Assaf Harofeh Medical Center, Zerifin, Israel.
Ronit Zaidenstein
Affiliation:
Department of Medicine A, Assaf Harofeh Medical Center, Zerifin, Israel
Keith S. Kaye
Affiliation:
Division of Infectious Diseases, Detroit Medical Center, Wayne State University, Detroit, Michigan, USA
Dror Marchaim*
Affiliation:
Unit of Infectious Diseases, Assaf Harofeh Medical Center, Zerifin, Israel Sackler School of Medicine, Tel-Aviv University, Tel-Aviv, Israel
*
Address correspondence to Dror Marchaim, MD, Unit of Infectious Diseases, Assaf Harofeh Medical Center, Zerifin, 70300, Israel ([email protected]).
Get access Rights & Permissions [Opens in a new window]

Abstract

A recent, frequently quoted study has suggested that for bloodstream infections (BSIs) due to extended-spectrum β-lactamase–producing Enterobacteriaceae (ESBL) Escherichia coli, treatment with β-lactam/β-lactamase inhibitors (BLBLIs) might be equivalent to treatment with carbapenems. However, the majority of BSIs originate from the urinary tract. A multicenter, multinational efficacy analysis was conducted from 2010 to 2012 to compare outcomes of patients with non-urinary ESBL BSIs who received a carbapenem (69 patients) vs those treated with piperacillin-tazobactam (10 patients). In multivariate analysis, therapy with piperacillin-tazobactam was associated with increased 90-day mortality (adjusted odds ratio, 7.9, P=.03). For ESBL BSIs of a non-urinary origin, carbapenems should be considered a superior treatment to BLBLIs.

Infect Control Hosp Epidemiol 2015;36(8):981–985

Type
Concise Communications
Information
Infection Control & Hospital Epidemiology , Volume 36 , Issue 8 , August 2015 , pp. 981 - 985
Copyright
© 2015 by The Society for Healthcare Epidemiology of America. All rights reserved 

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

Footnotes

*

Hadas Ofer-Friedman and Coral Shefler contributed equally to this publication.

References

1. Paterson, DL, Bonomo, RA. Extended-spectrum beta-lactamases: a clinical update. Clin Microbiol Rev 2005;18:657–686.CrossRefGoogle ScholarPubMed
2. Ben-Ami, R, Rodriguez-Bano, J, Arslan, H, et al. A multinational survey of risk factors for infection with extended-spectrum beta-lactamase-producing enterobacteriaceae in nonhospitalized patients. Clin Infect Dis 2009;49:682–690.CrossRefGoogle ScholarPubMed
3. Schwaber, MJ, Carmeli, Y. Mortality and delay in effective therapy associated with extended-spectrum beta-lactamase production in Enterobacteriaceae bacteraemia: a systematic review and meta-analysis. J Antimicrob Chemother 2007;60:913–920.CrossRefGoogle ScholarPubMed
4. Bush, K. Extended-spectrum beta-lactamases in North America, 1987–2006. Clin Microbiol Infect 2008;14(Suppl 1):134–143.CrossRefGoogle ScholarPubMed
5. Clinical and Laboratory Standards Institute. Performance standards for antimibrobial susceptibility testing. Nineteenth informational supplement. Approved standard M100-S19. Wayne, PA: CLSI, 2009.Google Scholar
6. Paterson, DL, Ko, WC, Von Gottberg, A, et al. Antibiotic therapy for Klebsiella pneumoniae bacteremia: implications of production of extended-spectrum beta-lactamases. Clin Infect Dis 2004;39:31–37.CrossRefGoogle ScholarPubMed
7. Zimhony, O, Chmelnitsky, I, Bardenstein, R, et al. Endocarditis caused by extended-spectrum-beta-lactamase-producing Klebsiella pneumoniae: emergence of resistance to ciprofloxacin and piperacillin-tazobactam during treatment despite initial susceptibility. Antimicrob Agents Chemother 2006;50:3179–3182.CrossRefGoogle ScholarPubMed
8. Drawz, SM, Bonomo, RA. Three decades of beta-lactamase inhibitors. Clin Microbiol Rev 2010;23:160–201.CrossRefGoogle ScholarPubMed
9. Bush, K. Bench-to-bedside review: The role of beta-lactamases in antibiotic-resistant Gram-negative infections. Crit Care 2010;14:224.CrossRefGoogle ScholarPubMed
10. Peleg, AY, Hooper, DC. Hospital-acquired infections due to gram-negative bacteria. N Engl J Med 2010;362:1804–1813.CrossRefGoogle ScholarPubMed
11. Rodriguez-Bano, J, Navarro, MD, Retamar, P, Picon, E, Pascual, A. Beta-lactam/beta-lactam inhibitor combinations for the treatment of bacteremia due to extended-spectrum beta-lactamase-producing Escherichia coli: a post hoc analysis of prospective cohorts. Clin Infect Dis 2012;54:167–174.CrossRefGoogle ScholarPubMed
12. Vardakas, KZ, Tansarli, GS, Rafailidis, PI, Falagas, ME. Carbapenems versus alternative antibiotics for the treatment of bacteraemia due to Enterobacteriaceae producing extended-spectrum beta-lactamases: a systematic review and meta-analysis. J Antimicrob Chemother 2012;67:2793–2803.CrossRefGoogle ScholarPubMed
13. Perez, F, Bonomo, RA. Can we really use ss-lactam/ss-lactam inhibitor combinations for the treatment of infections caused by extended-spectrum ss-lactamase-producing bacteria? Clin Infect Dis 2012;54:175–177.CrossRefGoogle ScholarPubMed
14. Wooley, M, Miller, B, Krishna, G, Hershberger, E, Chandorkar, G. Impact of renal function on the pharmacokinetics and safety of ceftolozane-tazobactam. Antimicrob Agents Chemother 2014;58:2249–2255.CrossRefGoogle ScholarPubMed
15. Sobel, JD. Pathogenesis of urinary tract infection. Role of host defenses. Infect Dis Clin North Am 1997;11:531–549.CrossRefGoogle ScholarPubMed
16. Retamar, P, Lopez-Cerero, L, Muniain, MA, Pascual, A, Rodriguez-Bano, J. Impact of the MIC of piperacillin-tazobactam on the outcome of patients with bacteremia due to extended-spectrum-beta-lactamase-producing Escherichia coli . Antimicrob Agents Chemother 2013;57:3402–3404.CrossRefGoogle ScholarPubMed
17. Marchaim, D, Sunkara, B, Lephart, PR, et al. Extended-spectrum beta-lactamase producers reported as susceptible to piperacillin-tazobactam, cefepime, and cefuroxime in the era of lowered breakpoints and no confirmatory tests. Infect Control Hosp Epidemiol 2012;33:853–855.CrossRefGoogle ScholarPubMed
18. Doi, Y, Park, YS, Rivera, JI, et al. Community-associated extended-spectrum beta-lactamase-producing Escherichia coli infection in the United States. Clin Infect Dis 2013;56:641–648.CrossRefGoogle ScholarPubMed
19. Lopez-Cerero, L, Navarro, MD, Bellido, M, et al. Escherichia coli belonging to the worldwide emerging epidemic clonal group O25b/ST131: risk factors and clinical implications. J Antimicrob Chemother 2014;69:809–814.CrossRefGoogle Scholar
20. Marchaim, D, Gottesman, T, Schwartz, O, et al. National multicenter study of predictors and outcomes of bacteremia upon hospital admission caused by Enterobacteriaceae producing extended-spectrum beta-lactamases. Antimicrob Agents Chemother 2010;54:5099–5104.CrossRefGoogle ScholarPubMed
21. Chopra, T, Marchaim, D, Veltman, J, et al. Impact of cefepime therapy on mortality among patients with bloodstream infections caused by extended-spectrum-beta-lactamase-producing Klebsiella pneumoniae and Escherichia coli . Antimicrob Agents Chemother 2012;56:3936–3942.CrossRefGoogle Scholar
22. Horan, TC, Andrus, M, Dudeck, MA. CDC/NHSN surveillance definition of health care-associated infection and criteria for specific types of infections in the acute care setting. Am J Infect Control 2008;36:309–332.CrossRefGoogle ScholarPubMed
23. Dellinger, RP, Levy, MM, Carlet, JM, et al. Surviving Sepsis Campaign: international guidelines for management of severe sepsis and septic shock: 2008. Crit Care Med 2008;36:296–327.CrossRefGoogle ScholarPubMed
24. Katz, S, Ford, AB, Moskowitz, RW, Jackson, BA, Jaffe, MW. Studies of illness in the aged. the index of ADL: a standardized measure of biological and psychosocial function. JAMA 1963;185:914–919.CrossRefGoogle Scholar
25. Charlson, ME, Pompei, P, Ales, KL, MacKenzie, CR. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis 1987;40:373–383.CrossRefGoogle ScholarPubMed
26. Bion, JF, Edlin, SA, Ramsay, G, McCabe, S, Ledingham, IM. Validation of a prognostic score in critically ill patients undergoing transport. Br Med J (Clin Res Ed) 1985;291:432–434.CrossRefGoogle ScholarPubMed
27. Collins, VL, Marchaim, D, Pogue, JM, et al. Efficacy of ertapenem for treatment of bloodstream infections caused by extended-spectrum-beta-lactamase-producing Enterobacteriaceae. Antimicrob Agents Chemother 2012;56:2173–2177.CrossRefGoogle ScholarPubMed
28. Carmeli, Y, Lidji, SK, Shabtai, E, Navon-Venezia, S, Schwaber, MJ, The effects of group. 1 versus group 2 carbapenems on imipenem-resistant Pseudomonas aeruginosa: an ecological study. Diagn Microbiol Infect Dis 2011;70:367–372.CrossRefGoogle ScholarPubMed